PCSK9 Inhibitor Market Size & Share 2025 - 2034

PCSK9 Inhibitor Market Size

The global PCSK9 inhibitor market size was valued at around USD 2.5 billion in 2024 and is estimated to grow at 19% CAGR from 2025 to 2034. The growing prevalence of disorders like familial hypercholesterolemia and atherosclerosis fuels the immediate demand for newer cholesterol management treatments, especially PCSK9 inhibitors.

For instance, the World Health Organization (WHO) has reported that in 2023, cardiovascular disease caused 32% of total deaths worldwide. Moreover, in 2022, approximately 39% of all adults worldwide were affected by hypercholesterolemia. This significant burden of disease explains the crucial significance of new cholesterol-lowering medications in public health policy.
 

Additionally, heightened awareness through public health campaigns and better patient education on the dangers of high LDL cholesterol have accelerated the adoption of PCSK9 inhibitors. Both patients and healthcare providers now recognize these medications as effective options for managing high cholesterol levels, resulting in enhanced treatment adherence rates.
 

Furthermore, access to PCSK9 inhibitors has improved in North America and Europe, driven by larger healthcare budgets and expanded reimbursement coverage for high-risk patients. For example, the National Health Expenditure reports that U.S. retail prescription drug spending increased 8.4% to USD 405.9 billion in 2022. Such healthcare spending growth during this period represents a tightening focus on managing cardiovascular disease within advanced healthcare systems, allowing wider use of biological therapies.
 

PCSK9 inhibitors are medications that lower low-density lipoprotein (LDL) cholesterol, commonly known as bad cholesterol. These drugs block proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that limits the liver's capacity to remove LDL cholesterol from blood. By blocking PCSK9, the medications increase LDL receptors on liver cells, enabling more efficient removal of LDL cholesterol from the bloodstream.
 

PCSK9 Inhibitor Market Trends

• The adoption of various PCSK9 inhibitors, such as Evolocumab (Repatha) and Alirocumab (Praluent), is increasing rapidly due to their efficacy in lowering LDL cholesterol, particularly in highly cardiovascular-risk patients, has become well established. Their clinical effectiveness has increased, and healthcare prescribers' rates have enhanced accordingly.
   
• Vendors are constantly focusing on cost reduction of PCSK9 inhibitors. According to the August 2021 article published by National Center for Biotechnology Information, the price reduction during 2015-2019 positively influenced the utilization of PCSK9 inhibitors among patients (especially among atherosclerotic cardiovascular disease patients), leading to higher prescription rates and better adherence to therapy.
   
• Furthermore, pharmaceutical companies are spending huge sums on research and development of new cholesterol-lowering drugs. For example, in August 2023, Merck & Co., Inc. announced the initiation of its Phase 3 clinical program, CORALreef, for MK-0616, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor investigational oral medicine.
   
• This drug was being evaluated for treatment of adults with hypercholesterolemia. These initiatives both stem from research need for additional treatments and the increasing market opportunity for cardiovascular disease management.
   

Trump Administration Tariffs

• The extension or reimposition of tariffs on Chinese drug substance ingredients and biotechnology components could raise the cost of producing PCSK9 inhibitors in the future, as most companies will continue to rely on Chinese-sourced APIs and intermediates.
   
• Should such tariffs continue, PCSK9 inhibitor producers will also reconsider their procurement strategies, possibly relocating production to other markets such as India or Eastern Europe to buffer costs and supply volatility.
   
• Additionally, future R&D efforts in the PCSK9 inhibitor market are expected to be slowed down if tariffs increase the cost of importing necessary lab reagents, specialized chemicals, and biotech equipment used in development and testing.
   
• International research collaborations with Chinese biotech and CRO companies might be discouraged by trade tensions, thereby reducing innovation and restricting global pipeline growth for PCSK9 inhibitor therapies.
   
• Furthermore, if tariffs affect components utilized in clinical trials, including biosample kits and diagnostic devices, trial conduct across international sites, particularly those involving Chinese sites, may be made more costly and logistically difficult.
   

PCSK9 Inhibitor Market Analysis

Based on drug, the market is segmented into alirocumab, evolocumab, inclisiran, and other drugs. The evolocumab segment dominated the market with the largest revenue share of 52.4% in 2024.
 

• Evolocumab is an important drug in cholesterol control by significantly lowering low-density lipoprotein (LDL) cholesterol levels. It is thus an important treatment for patients with high cholesterol, especially those at high risk for cardiovascular disease.
   
• Moreover, increasing incidence of hyperlipidemia and cardiovascular diseases globally is a key driver of such demand. For instance, according to the World Health Organization (WHO), cardiovascular diseases are the primary cause of mortality on a global scale, killing nearly 17.9 million people annually, highlighting the demand for successful cholesterol control products such as Evolocumab.

Learn more about the key segments shaping this market

Download Free PDF

Based on modality, the PCSK9 inhibitor market is segmented into fully-humanized monoclonal antibodies and siRNA. The fully-humanized monoclonal antibodies segment dominated the market with the largest revenue of USD 2.2 billion in 2024.
 

• Various clinical trials have proven the critical ability of fully-humanized monoclonal antibodies to lower both LDL cholesterol concentrations and the rates of cardiovascular events substantially. For instance, in May 2024, AstraZeneca reported favorable Phase I trial results for its PCSK9 inhibitor, AZD0708, that recorded a statistically significant decrease among patients suffering from hypercholesterolemia. Positive results like this one boost the confidence of healthcare professionals and patients, and subsequent adoption of these therapies.
   
• Furthermore, ongoing research in biotechnology has made it possible to develop fully-humanized monoclonal antibodies. Advances in process manufacturing, formulation techniques, and delivery systems have improved the overall safety and effectiveness of these treatments. As a result, patients are provided with improved treatment responses and greater compliance with treatment regimens.
   

Based on indication, the PCSK9 inhibitor market is segmented into hyperlipidemia, hypercholesterolemia, and cardiovascular diseases. The hypercholesterolemia segment dominated the market with the largest revenue of USD 1.5 billion in 2024.
 

• Growing prevalence of hypercholesterolemia and related cardiovascular conditions is fueling the need for efficient therapy that lowers cholesterol levels. For instance, as per the Centers for Disease Control and Prevention, almost 38% of adults in the United States suffer from high cholesterol levels, and therefore the demand for drugs like PCSK9 inhibitors. The immense health condition derives from the vital need for sophisticated cholesterol management therapies in addressing worldwide cardiovascular wellness issues.
   
• Moreover, the innovation of new PCSK9 inhibitors, monoclonal antibodies, and combination treatments with the help of biotechnology progress increases the options for available treatments. For example, in August 2023, Innovent Biologics, Inc. announced that China's National Medical Products Administration (NMPA) granted SINTBILO, a tafolecimab injection, anti-PCSK9 monoclonal antibody, approval to treat adult patients with primary hypercholesterolemia and mixed dyslipidemia. These indications seek to enhance patient compliance and outcomes, especially among patients who are unable to attain target levels of cholesterol using conventional statins.
   

Based on distribution channel, the PCSK9 inhibitor market is segmented into hospital pharmacies, retail pharmacies, and E-commerce. The hospital pharmacies segment dominated the market with the largest revenue of USD 1.4 billion in 2024.
 

• Many high-risk patients in need of immediate access to PCSK9 inhibitors utilize hospital pharmacies. They possess complex medical histories and are dependent upon hospital pharmacists' recommendations for the management of treatment.
   
• In addition, clinical guidelines currently prioritize PCSK9 inhibitors for patients who are not demonstrating sufficient cholesterol control with regular therapies. This has led to hospitals having PCSK9 inhibitor on hand, which allows for on-time treatment delivery.

North America: The U.S. PCSK9 inhibitor market is projected to grow significantly, reaching USD 5.9 billion by 2034.
 

• Owing to increasing concerns for cholesterol related disorders, the U.S. Food and Drug Administration (FDA) has provided an accelerated approval of PCSK9 inhibitors to enable quicker access to the valuable medicines available in the market.
   
• For example, in September 2021, evolocumab was approved by the FDA as a therapy for pediatric patients with heterozygous familial hypercholesterolemia (HeFH) to reduce LDL cholesterol levels. This regulatory support has increased healthcare provider confidence in prescribing PCSK9 inhibitors, thereby driving market growth.
   
• In addition, latest clinical guidelines promulgated by the American Heart Association (AHA) and the American College of Cardiology (ACC) have incorporated PCSK9 inhibitors as first choice therapies for subjects with high cardiovascular risk. Based on this prescription, prescription level has increased amongst physicians because they are more likely to prescribe treatments for individuals having high cholesterol levels.
   

Europe: PCSK9 inhibitor market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The increasing prevalence of hyperlipidemia and cardiovascular diseases in the UK largely fuels the demand for cholesterol-lowering treatments. For example, as per the British Heart Foundation, about 7.6 million individuals in the UK suffer from cardiovascular diseases. This increasing health issue leads to increased diagnosis rates and encourages the uptake of PCSK9 inhibitors, reflecting a positive growth trend for these treatments in the market.
   
• Additionally, the UK's NHS as well as its private insurance payers have reimbursement policies for PCSK9 inhibitors that enhance access to the drug by patients. These policies make it possible for eligible patients to undergo PCSK9 inhibitor treatment.
   

Asia Pacific: Japan PCSK9 inhibitor market is anticipated to witness lucrative growth between 2025 – 2034.
 

• Increasing elderly population of Japan largely is responsible for increased cases of hyperlipidemia and cardiovascular illnesses. For example, the average life expectancy at birth in Japan in 2023 was 87.14 years for women and 81.09 years for men, ranking it amongst the highest worldwide. This demographic pattern supplements the need for effective treatment options, such as PCSK9 inhibitors, for controlling cholesterol and lowering cardiovascular risks.
   
• Furthermore, the Japanese healthcare system also lays great stress on preventive care, which promotes the use of PCSK9 inhibitors for cholesterol control and cardiovascular risk reduction. The emphasis on prevention prompts healthcare professionals to incorporate these new treatments into routine medical practices, making them more accessible and usable for high-risk populations.
   

Middle East and Africa: PCSK9 inhibitor market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• There is a rising incidence of hyperlipidemia and cardiovascular diseases in Saudi Arabia, primarily due to lifestyle factors, unhealthy eating habits, and lack of exercise. For example, as the National Institutes of Health (NIH) indicates, cardiovascular disease causes 45.7% of all mortality in the nation, with high cholesterol being an identified risk factor.
   
• This large burden of disease generates demand for successful cholesterol-lowering therapies, such as PCSK9 inhibitors, among physicians responsible for the management of these conditions.
   
• Moreover, the Vision 2030 program in Saudi Arabia focuses on strategic investment in cutting-edge medical technologies and novel treatments to enhance the quality of healthcare throughout the country. This focus on upgrading healthcare infrastructure allows for the incorporation of new therapies, such as PCSK9 inhibitors, into clinical practice, thus enabling market expansion in the country.
   

PCSK9 Inhibitor Market Share

The market is competitive and fragmented, with both large global players and some small companies. Top 4 players in the market including Amgen, Sanofi, Regeneron Pharmaceuticals, and Novartis share over 90% of the market. One of the most important strategies for the participants is investment in the development of sophisticated PCSK9 inhibitors, including oral formulations, bispecific antibodies, precision medicine, and longer-acting formulations, to increase treatment efficiency.
 

Strategic collaborations with research centers and healthcare providers are essential strategies being pursued by the companies for the implementation of new technologies and widening distribution. This has made it possible for the companies to respond to increasing demand for inexpensive and non-invasive diagnostic alternatives. Increased attention towards compliance with regulatory requirements also fuels competition amongst companies in the market.
 

PCSK9 Inhibitor Industry News:

• In October 2024, Shanghai Junshi Biosciences announced the approval of its ongericimab injection, a recombinant human anti-PCSK9 monoclonal antibody, for the treatment of primary hypercholesterolemia and mixed dyslipidemia by the National Medical Products Administration. The approval is likely to improve Junshi Biosciences' product portfolio and enhance its position in the expanding market.
   
• In September 2020, AstraZeneca announced the acquisition of the preclinical oral PCSK9 inhibitor portfolio of Dogma Therapeutics. AstraZeneca had plans to take the program into clinical development for familial hypercholesterolemia and dyslipidemia. The deal is likely to add to AstraZeneca's lipid management portfolio and position it well in the market for cholesterol-reducing therapies, which is highly competitive.
   

PCSK9 Inhibitor Market Companies

Some of the eminent market participants operating in the PCSK9 inhibitor industry include:

• Akeso Biopharma
• Amgen
• Innovent
• Junshi Biosciences
• Novartis
• Regeneron Pharmaceuticals
• Sanofi
   
• Amgen has built a solid footprint in the market with Repatha (evolocumab), the first-ever monoclonal antibody that inhibits PCSK9. Repatha has strong clinical support with substantial LDL-C lowering and cardiovascular risk reduction. Amgen combines its cutting-edge biologics R&D, high-volume biologics production, and worldwide distribution network to stay at the forefront of this therapeutic category.
   
• Sanofi and Regeneron Pharmaceuticals co-market Praluent (alirocumab), another top PCSK9 inhibitor with proven efficacy in lowering LDL-C and cardiovascular events. Sanofi uses its large global commercial organization and expertise in lipid management to provide wide market access and physician coverage and actively promotes real-world evidence generation to reinforce long-term treatment benefit.
   
• Novartis is expanding its presence in the PCSK9 space with inclisiran (trade name Leqvio), a first-in-class small interfering RNA (siRNA)-targeting medicine. Differing from other traditional monoclonal antibodies, Leqvio has a dosing interval every six months, allowing better compliance by patients. Novartis draws upon its RNA-based innovation strength, selling on an enormous scale, along with partnership with payers and healthcare professionals, to power long-term uptake across target cardiovascular territories.
   

The PCSK9 inhibitor market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Drug

• Alirocumab
• Evolocumab
• Inclisiran
• Other drugs

Market, By Modality

• Fully-humanized monoclonal antibodies
• siRNA

Market, By Indication

• Hyperlipidemia
• Hypercholesterolemia
• Cardiovascular diseases

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• E-commerce

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands 
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE